The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Does acalabrutinib increase the risk of hypertension in patients with CLL?
Alessandra Ferrajoli, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses an analysis comparing the rate of new or worsening hypertension in patients with chronic lymphocytic leukemia (CLL) who were treated with acalabrutinib to real-world prevalence and incidence of hypertension in patients with CLL prior to treatment initiation. Although prior studies have shown increased rates of new or worsening hypertension when treating CLL with other BTK inhibitors (ibrutinib and zanubrutinib), this analysis determined that acalabrutinib monotherapy did not worsen pre-existing hypertension or increase the risk of new-onset hypertension. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Genetech, Janssen, AstraZeneca, Abbvie
Research Funding: GenMab, Beigene, AstraZeneca, Abbvie
